Adam Woodrow - 16 Aug 2021 Form 4 Insider Report for Paratek Pharmaceuticals, Inc. (PRTK)

Role
President & Chief Commercial
Signature
/s/ William M. Haskel, Attorney-in-Fact for Adam Woodrow
Issuer symbol
PRTK
Transactions as of
16 Aug 2021
Net transactions value
-$56,192
Form type
4
Filing time
18 Aug 2021, 19:11:38 UTC
Previous filing
08 Jun 2021
Next filing
15 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTK Common Stock Award $0 +37,500 +7.9% $0.000000 512,296 16 Aug 2021 Direct F1
transaction PRTK Common Stock Sale $56,192 -10,975 -2.1% $5.12 501,321 17 Aug 2021 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance-based restricted stock units ("PRSUs") granted on July 31, 2019 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on August 16, 2021.
F2 Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $5.02 to $5.22. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.